After $100M deal, J&J links gene therapy to improved vision in early-phase trial

Johnson & Johnson has posted clinical data on its $100 million gene therapy bet. The Big Pharma linked its inherited retinal disease candidate to improved vision in a phase 1/2 clinical trial, offering insights into how it may perform in an ongoing pivotal study.